GSK Deals for Epilepsy Drug


Aug. 28—GSK has entered a deal with Valeant to develop and market the epilepsy drug retigabine and other similar compounds. The agreement begins with a $125 million payment and could net Valeant $825 million, sales and royalties. Retigabine has been tested in two Phase III trials for epilepsy and is currently in Phase II trials for post-herpetic neuralgia. CNN Money 

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

IBM
DESKTOP ENGINEERING WITH IBM:
High Performance Cluster Computing Survey
Sponsored by IBM Platform Computing


Tessella logo
Target Analytics Maturity to Beat the Big Data Backlash
Sponsored by Tessella


New Medidata logo
Why Monitoring Is More Than Just SDV
Sponsored by Medidata


Life Science Webcasts & Podcasts

medidata_podcast_Sites and Sponsors: Mending Bridges over Troubled Waters  
Sites and Sponsors: Mending Bridges over Troubled Waters
Sponsored by Medidata Solutions Worldwide

This podcast brings together two industry leaders to focus on the issues that divide sponsors and sites. On the one hand sites and sponsors unite in advancing better health care through a common passion for developing better drugs. Yet some issues divide them and bridges need to be built or mended to advance the highest levels of cooperation, coordination and success in clinical trials. Listen as the key issues are debated from the site and the sponsor side and new methods and technology are advanced that offer near-term and lasting solutions.

• Common ground in reaching agreement on a budget

• Improving the pace of agreement on budgets and contracts

• Processes for payment to sites on a timely basis

Listen Now  

More Podcasts

Job Openings

For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.